Ophthalmology science · 2025
Risk Analysis of Retinal Hemangioblastomas in Nonadvanced Stages of von Hippel-Lindau Syndrome Using Ultra-widefield Imaging: The ULTRA von Hippel-Lindau Study.
СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Del Fabbro Sebastiano, Cicinelli Maria Vittoria, Lattanzio Rosangela, Bousyf Soufiane, Bruno Lorenza, Antropoli Alessio, Bianco Lorenzo, Bruschi Elena, Arrigo Alessandro, Pipitone Giovanni, Cei Francesco, Salerno Lucia, Larcher Alessandro, Salonia Andrea, Bandello Francesco, Battaglia Parodi Maurizio, OSR VHL Program
Аннотация
PURPOSE: To investigate the longitudinal progression, risk factors, and complications associated with retinal hemangioblastomas (RHs) in nonadvanced stages of von Hippel-Lindau (VHL) syndrome using ultra-widefield (UWF) imaging.
DESIGN: Single-center longitudinal cohort study.
SUBJECTS: Caucasian patients with genetically confirmed VHL syndrome.
METHODS: Annual evaluations included dilated fundus examinations, UWF pseudocolor fundus retinal images, UWF fluorescein angiography, and OCT. Genetic analysis classified VHL mutations. Baseline RH counts and anatomical distributions were recorded as central (juxtapapillary, macular), peripheral, or both. Longitudinal follow-up tracked new RH formation and visual acuity (VA) values.
MAIN OUTCOME MEASURES: Cumulative incidence, incidence rate ratios (IRRs), and risk factors of new RHs assessed using mixed-effects negative binomial regression models. Hazard of recurrent RHs evaluated through Cox frailty models and longitudinal changes in VA.
RESULTS: Among 78 eyes of 43 patients (mean age: 47.8 ± 13.6 years), 110 RHs were documented at baseline, with 3 (3%) centrally located, 35 (32%) peripherally, and 72 (65%) spanning both zones. von Hippel-Lindau variants were investigated in 37 patients: 19 had missense variants (51%), and 18 had presumed null alleles (49%), including nonsense (10 of 37; 27%), frameshift (1 of 37; 3%), splice site (1 of 37; 3%), and exon deletion mutations (6 of 37; 16%). Over a median follow-up of 31 months (interquartile range: 27-109), 35 (43%) eyes developed new RHs, with an incidence rate of 0.22 RHs per eye-year (95% confidence interval: 0.17-0.27). By the last available examination, 26 eyes (34%) remained disease-free, whereas17 (23%) showed no progression of existing RHs. Age reduced the IRR of new RHs by 4.2% annually (P = 0.003), whereas higher baseline tumor burden and vascular leakage increased the IRR significantly (P < 0.001 and P = 0.03, respectively). Peripheral RHs were the strongest predictor of recurrence (hazard ratio = 16.4, P < 0.001), whereas older age remained protective (hazard ratio = 0.96, P = 0.04). Visual acuity (logarithm of the minimum angle of resolution) worsened from 0.05 ± 0.2 (Snellen equivalent: 20/22) at baseline to 0.11 ± 0.3 (Snellen equivalent: 20/25) at the final visit.
CONCLUSIONS: Peripheral RHs and vascular leakage are significant risk factors for RH progression and recurrence in VHL syndrome. Although older age provides a protective effect, close monitoring of high-risk eyes is essential to enable timely intervention and preserve vision.
FINANCIAL DISCLOSURES: Proprietary or commercial disclosure may be found in the Footnotes and Disclosures at the end of this article.
DESIGN: Single-center longitudinal cohort study.
SUBJECTS: Caucasian patients with genetically confirmed VHL syndrome.
METHODS: Annual evaluations included dilated fundus examinations, UWF pseudocolor fundus retinal images, UWF fluorescein angiography, and OCT. Genetic analysis classified VHL mutations. Baseline RH counts and anatomical distributions were recorded as central (juxtapapillary, macular), peripheral, or both. Longitudinal follow-up tracked new RH formation and visual acuity (VA) values.
MAIN OUTCOME MEASURES: Cumulative incidence, incidence rate ratios (IRRs), and risk factors of new RHs assessed using mixed-effects negative binomial regression models. Hazard of recurrent RHs evaluated through Cox frailty models and longitudinal changes in VA.
RESULTS: Among 78 eyes of 43 patients (mean age: 47.8 ± 13.6 years), 110 RHs were documented at baseline, with 3 (3%) centrally located, 35 (32%) peripherally, and 72 (65%) spanning both zones. von Hippel-Lindau variants were investigated in 37 patients: 19 had missense variants (51%), and 18 had presumed null alleles (49%), including nonsense (10 of 37; 27%), frameshift (1 of 37; 3%), splice site (1 of 37; 3%), and exon deletion mutations (6 of 37; 16%). Over a median follow-up of 31 months (interquartile range: 27-109), 35 (43%) eyes developed new RHs, with an incidence rate of 0.22 RHs per eye-year (95% confidence interval: 0.17-0.27). By the last available examination, 26 eyes (34%) remained disease-free, whereas17 (23%) showed no progression of existing RHs. Age reduced the IRR of new RHs by 4.2% annually (P = 0.003), whereas higher baseline tumor burden and vascular leakage increased the IRR significantly (P < 0.001 and P = 0.03, respectively). Peripheral RHs were the strongest predictor of recurrence (hazard ratio = 16.4, P < 0.001), whereas older age remained protective (hazard ratio = 0.96, P = 0.04). Visual acuity (logarithm of the minimum angle of resolution) worsened from 0.05 ± 0.2 (Snellen equivalent: 20/22) at baseline to 0.11 ± 0.3 (Snellen equivalent: 20/25) at the final visit.
CONCLUSIONS: Peripheral RHs and vascular leakage are significant risk factors for RH progression and recurrence in VHL syndrome. Although older age provides a protective effect, close monitoring of high-risk eyes is essential to enable timely intervention and preserve vision.
FINANCIAL DISCLOSURES: Proprietary or commercial disclosure may be found in the Footnotes and Disclosures at the end of this article.